Opus Genetics
IRD
26 hedge funds and large institutions have $2.62M invested in Opus Genetics in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 6 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
7% less funds holding
Funds holding: 28 → 26 (-2)
20% less capital invested
Capital invested by funds: $3.28M → $2.62M (-$667K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$306K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$55.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12K |
| 4 |
NWM
Northwest Wealth Management
Spencer,
Iowa
|
+$7.54K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$7.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$38K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$37K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$34.7K |
| 4 |
VF
Virtu Financial
New York
|
-$30K |
| 5 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$27.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$37K | -380 | Closed |
|
|
VF
27
Virtu Financial
New York
| – | -$30K | -305 | Closed |
|
|
TSS
28
Two Sigma Securities
New York
| – | -$24K | -250 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$272 | -3 | -25% |
|
30
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$182 | +2 | New |
|
|
TC
31
Trilogy Capital
Irvine,
California
| – | +$363 | +4 | New |
|
IRD Hedge Fund Activity: Q1 2018 in Review
26 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2018, worth a combined $2.62M — down 20% from $3.28M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IRD and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $306K. The largest seller was Citadel Advisors, exiting entirely with an estimated $38K sold.
- 26 institutional investors held Opus Genetics (IRD) as of Q1 2018, down from 28 in Q4 2017.
- Funds reported $2.62M of Opus Genetics stock for Q1 2018, down 20% quarter-over-quarter.
- 4 funds opened new Opus Genetics positions in Q1 2018 and 6 closed out, a net change of -2 holders.
- The largest Opus Genetics buyer in Q1 2018 was Vanguard Group, an estimated $306K added.
- The largest Opus Genetics seller in Q1 2018 was Citadel Advisors, an estimated $38K sold.
Based on aggregated 13F filings for Q1 2018.